RxDoctor Payments Data

Tonya Rushing

Primary Care · Flowood, MSNPI 1922653849

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 35.0% of the total. Reporting peaked in 2024 at $441 and has fallen 72.2% since, to $123 in 2025.

$833in general payments, 2019–2025

Across 41 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$291
  • AstraZeneca$204
  • Novo Nordisk$65
  • Neurocrine Biosciences, Inc.$61
  • Lilly USA, LLC$60
  • Amgen$33
  • plus $118 from 6 others

What the payments were for

  • Food & beverage$833100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$833 in reported general payments places this provider in the 65th percentile of 80 primary care providers in Mississippi.

See all primary care providers in Mississippi

Medicare billing

Part B allowed, 2024
$19,220
Medicare patients
63
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,926
Omega-3 Acid Ethyl Esters22$677
SynthroidLevothyroxine Sodium14$634
Albuterol Sulfate HfaAlbuterol Sulfate17$552
Pregabalin14$422
Potassium Chloride37$379
Metoprolol Succinate37$336
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen24$297
Gabapentin37$249
Pravastatin Sodium30$232
Duloxetine Hcl34$230
Tizanidine Hcl55$229
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$210
Levocetirizine Dihydrochloride34$207
Nystatin13$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$291$63414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 80 primary care providers in Mississippi.

Other primary care in Flowood

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →